共 54 条
[1]
Haddy F.J., Overbeck H.W., The role of humoral agents in volume expanded hypertension, Life Sci, 19, pp. 935-948, (1976)
[2]
Mize-Songu E., Bealer S.L., Caldwell R., Effect of DOCA-salt treatment duration and anteroventral third ventricle lesions on a plasma-borne sodium pump inhibitor in rats, J Hypertens, 5, pp. 461-467, (1987)
[3]
Kramer H.J., Meyer-Lehnert H., Michel H., Predel H.-G., Endogenous natriuretic and ouabain-like factor. Their roles in body fluid volume and blood pressure regulation, Am J Hypertens, 4, pp. 81-89, (1991)
[4]
De Wardener H.E., Kidney, salt intake, and Na +, K+- ATPase inhibitors in hypertension, Hypertension, 17, pp. 830-835, (1991)
[5]
De Wardener H.E., Mills I.H., Clapham W.F., Hayter C.J., Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog, Clin Sci, 21, pp. 249-258, (1961)
[6]
Gruber K.A., Whitaker J.M., Buckalew V.M., Endogenous digitalis–like substance in plasma of volume-expanded dogs, Nature, 287, pp. 743-745, (1980)
[7]
Hasegawa T., Masugi F., Ogihara T., Kumahara Y., Increase in plasma ouabain-like inhibitor of Na +, K+- ATPase with high sodium intake in patients with essential hypertension, J Clin Hypertens, 3, pp. 419-429, (1987)
[8]
Masugi F., Ogihara T., Hasegawa T., Et al., Circulating factor with ouabain-like immunoreactivity in patients with primary aldosteronism, Biochem Biophys Res Commun, 135, pp. 41-15, (1986)
[9]
Masugi F., Ogihara T., Hasegawa T., Kumahara Y., Ouabain-like and non-ouabain-like factors in plasma of patients with essential hypertension, Clin Exp Hypertens [A], 9, pp. 1233-1242, (1987)
[10]
Mir M.A., Difficulties in the isolation and identification of endogenous ouabain-like substances, Prog Biochem Pharmacol, 23, pp. 1-9, (1991)